Related Experiment Videos
Ornithine transcarbamylase deficiency
1Department of Pediatrics, National Taiwan University Hospital, Taipei, ROC.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|January 1, 1997
Summary
Ornithine transcarbamylase (OTC) deficiency, a common urea cycle disorder, was diagnosed in two infants presenting with hyperammonemia. Early treatment with medications and dietary changes effectively managed ammonia levels, highlighting the importance of prompt intervention.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Ornithine transcarbamylase (OTC) deficiency is a prevalent urea cycle disorder.
- X-linked genetic disorders can manifest differently in males and females.
Observation:
- Two infants, one male and one female, presented with elevated serum ammonia levels.
- Urine organic acid analysis and DNA studies confirmed OTC deficiency in both infants.
- Hyperammonemia onset occurred within the first week of life for both infants.
Findings:
- Sodium benzoate and sodium phenylacetate administration effectively reduced serum ammonia levels.
- Peritoneal dialysis and protein restriction were crucial in managing hyperammonemia.
- Genetic analysis identified the OTC gene mutation in the male infant's mother, indicating carrier status.
- The female infant's mutation site was identified, but her mother was not a carrier, suggesting a de novo mutation.
Implications:
- Prompt diagnosis and treatment are critical for managing OTC deficiency, even in female patients.
- Effective management involves a combination of pharmacotherapy, dietary modifications, and supportive therapies.
- Accurate genetic counseling is essential for families affected by OTC deficiency due to its X-linked inheritance pattern.